FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2330125535> ?p ?o ?g. }

• W2330125535 endingPage "640" @default.
• W2330125535 startingPage "629" @default.
• W2330125535 abstract "Baseline levels of innate and adaptive immune cell functions were studied in patients with pancreatic cancer. The effects of pemetrexed were measured at 7 and 14 days after initial therapy then 14 days after combination therapy with gemcitabine. Pretherapy levels of absolute numbers of natural killer (NK) cells positively correlated with survival. Cytolytic units of NK activity correlated positively with NK cell numbers. Pemetrexed decreased NK cytolytic units to significance when combined with gemcitabine. Pemetrexed increased intracellular accumulation of interferon gamma (IFNγ) in NK cells that correlated negatively with survival. Addition of gemcitabine decreased IFNγ-producing NK cells to baseline. Memory (CD45RO*) T cells enumerated at baseline correlated negatively with survival but were decreased by pemetrexed therapy. Memory T cells were increased in subjects with greater B7-H3 expression in tumor tissue, whereas OX40*-activated total T cells and helper T-cell subset were decreased. FoxP3*, CD8* T cells correlated positively with progression-free interval and survival. In conclusion, innate NK-cell immunity and FoxP3*, CD8* T cells seemed beneficial to pancreatic cancer patients. Higher levels of B7-H3 expression in pancreatic tumors were detrimental to effective immunity. Although pemetrexed therapy increased activation of a subset of NK cells to produce IFNγ, addition of gemcitabine abated those responses, decreasing IFNγ-producing NK cells, whereas NK cells producing interleukin-2 without IFNγ at this timepoint positively correlated with survival. Innate immunity and adaptive immunity thus are important in defense against pancreatic cancer. Progression-free interval and survival were longer than observed in a phase III trial where gemcitabine preceded pemetrexed suggesting that a larger trial of pemetrexed preceding gemcitabine is warranted." @default.
• W2330125535 created "2016-06-24" @default.
• W2330125535 creator A5002002024 @default.
• W2330125535 creator A5025108193 @default.
• W2330125535 creator A5035263938 @default.
• W2330125535 creator A5038805449 @default.
• W2330125535 creator A5042435594 @default.
• W2330125535 creator A5045997053 @default.
• W2330125535 creator A5055583723 @default.
• W2330125535 creator A5066864976 @default.
• W2330125535 creator A5082050561 @default.
• W2330125535 creator A5085534026 @default.
• W2330125535 date "2012-10-01" @default.
• W2330125535 modified "2023-10-16" @default.
• W2330125535 title "Effect of Pemetrexed on Innate Immune Killer Cells and Adaptive Immune T Cells in Subjects With Adenocarcinoma of the Pancreas" @default.
• W2330125535 doi "https://doi.org/10.1097/cji.0b013e31826c8a4f" @default.
• W2330125535 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22996369" @default.
• W2330125535 hasPublicationYear "2012" @default.
• W2330125535 type Work @default.
• W2330125535 sameAs 2330125535 @default.
• W2330125535 citedByCount "52" @default.
• W2330125535 countsByYear W23301255352013 @default.
• W2330125535 countsByYear W23301255352014 @default.
• W2330125535 countsByYear W23301255352015 @default.
• W2330125535 countsByYear W23301255352016 @default.
• W2330125535 countsByYear W23301255352017 @default.
• W2330125535 countsByYear W23301255352018 @default.
• W2330125535 countsByYear W23301255352019 @default.
• W2330125535 countsByYear W23301255352020 @default.
• W2330125535 countsByYear W23301255352021 @default.
• W2330125535 countsByYear W23301255352022 @default.
• W2330125535 countsByYear W23301255352023 @default.
• W2330125535 crossrefType "journal-article" @default.
• W2330125535 hasAuthorship W2330125535A5002002024 @default.
• W2330125535 hasAuthorship W2330125535A5025108193 @default.
• W2330125535 hasAuthorship W2330125535A5035263938 @default.
• W2330125535 hasAuthorship W2330125535A5038805449 @default.
• W2330125535 hasAuthorship W2330125535A5042435594 @default.
• W2330125535 hasAuthorship W2330125535A5045997053 @default.
• W2330125535 hasAuthorship W2330125535A5055583723 @default.
• W2330125535 hasAuthorship W2330125535A5066864976 @default.
• W2330125535 hasAuthorship W2330125535A5082050561 @default.
• W2330125535 hasAuthorship W2330125535A5085534026 @default.
• W2330125535 hasConcept C121608353 @default.
• W2330125535 hasConcept C126322002 @default.
• W2330125535 hasConcept C129374314 @default.
• W2330125535 hasConcept C136449434 @default.
• W2330125535 hasConcept C149532602 @default.
• W2330125535 hasConcept C154317977 @default.
• W2330125535 hasConcept C167672396 @default.
• W2330125535 hasConcept C193419808 @default.
• W2330125535 hasConcept C202751555 @default.
• W2330125535 hasConcept C203014093 @default.
• W2330125535 hasConcept C2776694085 @default.
• W2330125535 hasConcept C2777240266 @default.
• W2330125535 hasConcept C2778239845 @default.
• W2330125535 hasConcept C2779727006 @default.
• W2330125535 hasConcept C2780210213 @default.
• W2330125535 hasConcept C2780258809 @default.
• W2330125535 hasConcept C502942594 @default.
• W2330125535 hasConcept C55493867 @default.
• W2330125535 hasConcept C71924100 @default.
• W2330125535 hasConcept C86803240 @default.
• W2330125535 hasConcept C8891405 @default.
• W2330125535 hasConceptScore W2330125535C121608353 @default.
• W2330125535 hasConceptScore W2330125535C126322002 @default.
• W2330125535 hasConceptScore W2330125535C129374314 @default.
• W2330125535 hasConceptScore W2330125535C136449434 @default.
• W2330125535 hasConceptScore W2330125535C149532602 @default.
• W2330125535 hasConceptScore W2330125535C154317977 @default.
• W2330125535 hasConceptScore W2330125535C167672396 @default.
• W2330125535 hasConceptScore W2330125535C193419808 @default.
• W2330125535 hasConceptScore W2330125535C202751555 @default.
• W2330125535 hasConceptScore W2330125535C203014093 @default.
• W2330125535 hasConceptScore W2330125535C2776694085 @default.
• W2330125535 hasConceptScore W2330125535C2777240266 @default.
• W2330125535 hasConceptScore W2330125535C2778239845 @default.
• W2330125535 hasConceptScore W2330125535C2779727006 @default.
• W2330125535 hasConceptScore W2330125535C2780210213 @default.
• W2330125535 hasConceptScore W2330125535C2780258809 @default.
• W2330125535 hasConceptScore W2330125535C502942594 @default.
• W2330125535 hasConceptScore W2330125535C55493867 @default.
• W2330125535 hasConceptScore W2330125535C71924100 @default.
• W2330125535 hasConceptScore W2330125535C86803240 @default.
• W2330125535 hasConceptScore W2330125535C8891405 @default.
• W2330125535 hasIssue "8" @default.
• W2330125535 hasLocation W23301255351 @default.
• W2330125535 hasLocation W23301255352 @default.
• W2330125535 hasOpenAccess W2330125535 @default.
• W2330125535 hasPrimaryLocation W23301255351 @default.
• W2330125535 hasRelatedWork W1556307916 @default.
• W2330125535 hasRelatedWork W2103515427 @default.
• W2330125535 hasRelatedWork W2141330728 @default.
• W2330125535 hasRelatedWork W2330125535 @default.
• W2330125535 hasRelatedWork W2366649094 @default.
• W2330125535 hasRelatedWork W2946615038 @default.
• W2330125535 hasRelatedWork W4206425682 @default.
• W2330125535 hasRelatedWork W4286560817 @default.

• next